Adaptyx is pioneering a programmable biowearable platform for continuous, multi-analyte molecular monitoring through a small wearable patch. At the core of Adaptyx's technology are synthetic DNA-based molecular switches that enable continuous, lab-grade molecular sensing. This sensing capability powers the patch's ability to collect and stream continuous biochemical data, supporting earlier interventions and more precise, AI-assisted care across both clinical and everyday health applications. Founded in 2022 and based in Menlo Park, CA, the company is pursuing FDA clearance for clinical applications initially, with plans to expand into broader health and wellness markets.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/20/25 | $14,000,000 | Seed |
Cantos Ventures Chan Zuckerberg Biohub Network Humba Ventures Hyperlink Ventures Interlagos  Overwater Ventures Seaside Ventures Stanford University Starbloom Capital | undisclosed |
